These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 21328441

  • 1. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
    Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R.
    Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA, Barner JC.
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [Abstract] [Full Text] [Related]

  • 4. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [Abstract] [Full Text] [Related]

  • 5. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, Yuce H.
    Health Qual Life Outcomes; 2019 Oct 16; 17(1):155. PubMed ID: 31619251
    [Abstract] [Full Text] [Related]

  • 6. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.
    Pediatr Blood Cancer; 2013 May 16; 60(5):828-35. PubMed ID: 23335275
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
    Lanzkron S, Haywood C, Fagan PJ, Rand CS.
    J Health Care Poor Underserved; 2010 Feb 16; 21(1):277-86. PubMed ID: 20173269
    [Abstract] [Full Text] [Related]

  • 9. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
    Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R.
    Ann Pharmacother; 2011 Mar 16; 45(3):342-9. PubMed ID: 21325098
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The cost of health care for children and adults with sickle cell disease.
    Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG.
    Am J Hematol; 2009 Jun 16; 84(6):323-7. PubMed ID: 19358302
    [Abstract] [Full Text] [Related]

  • 12. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
    Armstrong EP, Skrepnek GH, Sasane M, Snodgrass SM, Ballas SK.
    J Med Econ; 2013 Jun 16; 16(1):10-8. PubMed ID: 22947171
    [Abstract] [Full Text] [Related]

  • 13. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL.
    Clin Ther; 2006 Oct 16; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [Abstract] [Full Text] [Related]

  • 14. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
    de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P, French Study Group on Sickle Cell Disease.
    Haematologica; 2006 Jan 16; 91(1):125-8. PubMed ID: 16434381
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.
    J Med Econ; 2016 Jan 16; 19(3):292-303. PubMed ID: 26618853
    [Abstract] [Full Text] [Related]

  • 17. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F, Bejaoui M.
    Arch Pediatr; 2008 Jan 16; 15(1):24-8. PubMed ID: 18164913
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
    Davis KL, Edin HM, Allen JK.
    Mov Disord; 2010 Mar 15; 25(4):474-80. PubMed ID: 20131374
    [Abstract] [Full Text] [Related]

  • 19. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.
    Am J Geriatr Pharmacother; 2009 Oct 15; 7(5):262-70. PubMed ID: 19948302
    [Abstract] [Full Text] [Related]

  • 20. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A, Jerrell JM, Stallworth JR.
    Pediatr Blood Cancer; 2011 Jan 15; 56(1):90-4. PubMed ID: 20922765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.